Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Merck characterizes new orally bioavailable thrombin inhibitor: L-374087

May 18, 1998

Corvas' small-protein antithrombotic enters U.S. clinical trials

May 15, 1998

FDA issues nonapprovable letter for Novastan

May 14, 1998

YM-337 shows therapeutic potential for the treatment of coronary thrombosis

May 12, 1998

Fibrin sealant approved for marketing in U.S.

May 11, 1998

Antithrombotics developed at Proteus available for licensing

May 11, 1998

NCX-4016: a nitroderivative of aspirin with increased antiplatelet activity

May 7, 1998

Results of Neutralase phase II trial presented

May 6, 1998

Profile of a factor Xa inhibitor in development at Yamanouchi

May 6, 1998

FDA advisory committee recommends approval of Aggrastat

May 4, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...